TY - JOUR AU - Langley, Joanne AU - Gantt, Soren AU - Quach, Caroline AU - Bettinger, Julie AU - Halperin, Scott AU - Mutch, Jill AU - McNeil, Shelly AU - Ward, Brian AU - MacKinnon-Cameron, Donna AU - Ye, Lingyun AU - Marty, Kim AU - Scheifele, David AU - Brown, Erin AU - Alcantara, Joenel T1 - Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada T2 - Emerging Infectious Disease journal PY - 2020 VL - 26 IS - 3 SP - 454 SN - 1080-6059 AB - Emergency vaccination programs often are needed to control outbreaks of meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) on college campuses. Such campaigns expend multiple campus and public health resources. We conducted a randomized, controlled, multicenter, observer-blinded trial comparing immunogenicity and tolerability of an accelerated vaccine schedule of 0 and 21 days to a longer interval of 0 and 60 days for 4-component MenB vaccine (MenB-4C) in students 17–25 years of age. At day 21 after the first MenB-4C dose, we observed protective human serum bactericidal titers >4 to MenB strains 5/99, H44/76, and NZ 98/254 in 98%–100% of participants. Geometric mean titers increased >22-fold over baseline. At day 180, >95% of participants sustained protective titers regardless of their vaccine schedule. The most common adverse event was injection site pain. An accelerated MenB-4C immunization schedule could be considered for rapid control of campus outbreaks. KW - Neisseria meningitidis Group B KW - meningitis KW - disease outbreaks KW - disease prevention KW - vaccines KW - humans KW - student health services KW - vaccine trial KW - meningococcal vaccine KW - bacteria KW - Canada KW - Neisseria meningitidis serogroup B KW - meningococcus serogroup B KW - meningitis/encephalitis KW - prevention KW - 4C-MenB KW - adolescents KW - young adults DO - 10.3201/eid2603.190160 UR - https://wwwnc.cdc.gov/eid/article/26/3/19-0160_article ER - End of Reference